中東およびアフリカの肺がん診断市場、製品タイプ別（機器、消耗品、付属品）、検査タイプ別（バイオマーカー検査、画像検査、生検、血液検査、その他）、がんタイプ別（非小細胞肺がん、小細胞肺がん）、エンドユーザー別（病院、関連研究所、独立診断研究所、診断画像センター、がん研究機関、その他）、流通チャネル別（直接入札、小売販売） - 2030年までの業界動向と予測。
中東およびアフリカの肺がん診断市場の分析と洞察
中東およびアフリカの肺がん診断市場は、市場プレーヤーの増加と高度なサービスの利用可能性により、予測年度に成長すると予想されています。これに伴い、メーカーは市場で新しいサービスを開始するための研究開発活動に取り組んでいます。肺がんの診断と開発研究の増加により、市場の成長がさらに促進されると予測されています。ただし、肺がんのスクリーニング技術の難しさにより、予測期間中の中東およびアフリカの肺がん診断市場の成長が妨げられる可能性があります。
がんの診断と治療に対する医療費の増加は、市場に治療を強化する機会を与えると予想されます。しかし、検査のコストの高さと、がん診断製品の承認と商品化に対する厳しい規制と基準が、市場の成長を妨げる可能性があります。
中東およびアフリカの肺がん診断市場は、病気の進行を抑えることを目標としており、支援的である。データブリッジマーケットリサーチは、中東およびアフリカの肺がん診断市場は、2023年から2030年の予測期間中に9.7%のCAGRで成長すると分析している。
|
レポートメトリック |
詳細 |
|
予測期間 |
2023年から2030年 |
|
基準年 |
2022 |
|
歴史的な年 |
2021 (2020 - 2015 にカスタマイズ可能) |
|
定量単位 |
売上高は百万米ドル、価格は米ドル |
|
対象セグメント |
製品タイプ別（機器、消耗品、付属品）、検査タイプ別（バイオマーカー検査、画像検査、生検、血液検査、その他）、がん種別（非小細胞肺がん、小細胞肺がん）、エンドユーザー別（病院、関連研究所、独立診断研究所、診断画像センター、がん研究機関、その他）、流通チャネル別（直接入札、小売販売） |
|
対象国 |
南アフリカ、サウジアラビア、UAE、エジプト、オマーン、バーレーン、カタール、クウェート、その他の中東およびアフリカ諸国 |
|
対象となる市場プレーヤー |
F. Hoffmann-La Roche Ltd.、Thermo Fisher Scientific Inc.、Abbott、Quest Diagnostics Incorporated、Biodesix、Amoy Diagnostics Co., Ltd.、Bio-Rad Laboratories, Inc.、Biocartis、Boditech Med Inc.、Danaher、Vela Diagnostics、DiaSorin SpA、Exact Sciences UK, Ltd. (Exact Science Corporation の子会社)、20/20 Gene Systems、Guardant Health, Inc.、Inivata Ltd.、LalPathLabs.com、LungLife AI, Inc.、MedGenome、Myriad Genetics, Inc.、NeoGenomics Laboratories、NanoString、Nanoentek、Oncocyte Corporation、PerkinElmer Inc.、PlexBio、QIAGEN、Siemens Healthcare GmbH、Veracyte, Inc. など |
市場の定義
がんは肺で発生し、喫煙者に最も多く発生します。肺がんの主な 2 つのタイプは、非小細胞肺がんと小細胞肺がんです。肺がんの原因には、喫煙、受動喫煙、特定の毒素への曝露、家族歴などがあります。
症状には、咳（血を伴うことが多い）、胸痛、喘鳴、体重減少などがあります。これらの症状は、がんが進行するまで現れないことがよくあります。治療法はさまざまですが、手術、化学療法、放射線療法、標的薬物療法、免疫療法などがあります。
中東およびアフリカの肺がん診断市場の動向
このセクションでは、市場の推進要因、利点、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。
- 肺がんの早期診断の増加
機械学習は、コンピューターに複雑なデータのパターンを見分けるトレーニングを行い、がんの早期診断に革命を起こす可能性があります。ツールには、一般的な健康データ、医療画像、生検サンプル、血液検査の評価などがあり、早期診断とリスク層別化に役立ちます。多くの腫瘍の種類では、がんの早期診断によって治療が成功する確率が高まります。重要な戦略の 1 つは、症状を示さないリスクのある患者を評価し、症状のある患者には迅速かつ適切に対応することです。
がんを早期に発見することで、がん治療が成功する確率が大幅に高まります。がんの早期発見には、スクリーニングと早期診断（またはダウンステージング）という 2 つの要素があります。スクリーニングは、症状が現れる前に健康な個人を評価してがん患者を見つけることですが、早期診断は症状のある患者を可能な限り早期に特定することに重点を置いています。
- 早期がんの検出は、偽陽性率が高く、感度が低いために制限されることが多い
The creation of non-invasive tests that can quickly and reliably identify whether and where in the body a person has early-stage cancer is one of the most promising areas of cancer prevention research. And not just one cancer but a variety of cancers. On this front, significant advancements have been made in recent years. Several multi-cancer early detection (MCED) tests are currently under development, and they are designed to screen for multiple cancer types in otherwise healthy individuals simultaneously. However, detecting early-stage cancer is a challenge as it comes with many barriers, such as high false positives or poor sensitivity. Many cases of poor diagnostics sensitivity lead to a patient's life at risk. The high false positives are also one of the causes of cancer advancing to late stages or advanced stages.
Thus, the detection of early-stage cancers is often limited by high false positives, and sometimes poor sensitivity may act as a major restraining factor for the growth of the Middle East and Africa lung cancer diagnostics market.
- Rise in healthcare expenditure for cancer diagnosis and treatment
Across the globe, research and development activities are escalating owing to the public health expenditure with economic performances. Whereas the healthcare industry ranks second among all industries when it comes to the amount spent on healthcare. Rising healthcare expenditure can result in better provision of research and development opportunities. It is anticipated to increase the demand for lung cancer diagnostics. Increasing the healthcare expenditure for cancer treatment also helps the patient take hassle-free advanced diagnostics and treatment for fast recovery. The spending on healthcare is made up of the combination of out-of-pocket payments (people paying for their care), government expenditure, and sources. It also includes health insurance and activities by non-governmental organizations. This increasing healthcare expenditure for cancer treatment is an opportunity to grow the market's demand.
- Lack of skilled and certified professionals
The requirement of skilled and certified professionals is a big restraint for cancer diagnostics. The demand for cancer diagnostic is increased due to increasing cases of cancer disease in the globe, but the fewer number of skilled professionals present in the diagnostic center is hampering the growth of the market.
The instruments, methods, and procedures of cancer diagnosis have been advanced, but there are certain gaps in standardization, equalization, and knowledge. Technicians face technical training gaps related to problems and adapt advanced methods safely to perform procedures efficiently. In cancer diagnostics, skilled professionals are highly needed for method development, validation, operation, and troubleshooting activities.
がんの診断は、今日の複雑な時代において動的な要素であり、患者にがんの診断、予防、治療、管理に不可欠な情報を提供します。訓練を受けたスタッフの必要性は、中東およびアフリカの肺がん診断市場にとって大きな問題です。熟練した資格のある専門家が不足しているため、エンドユーザーはがん診断用の高度な製品をインストールできず、これが中東およびアフリカの肺がん診断市場の成長を妨げる可能性があります。
COVID-19後の中東・アフリカの肺がん診断市場への影響
COVID-19が世界中の医療システムに及ぼす大きな負担により、腫瘍内科医の間では、COVID-19が肺がんの診断と治療に与える影響について懸念が高まっています。私たちは、この後ろ向きコホート研究で、COVID-19の前後で肺がんの診断と治療にCOVID-19が及ぼす影響を調査しました。パンデミックの間、COVID-19以前と比較して、新しい肺がんの診断は34.7％減少し、病気の進行期はわずかに増加し、最初の根治的治療としての放射線手術が大幅に増加し、全身治療と手術は減少しました。COVID-19以前と比較して、パンデミック中に化学療法と放射線治療の開始に大きな遅れはありませんでした。
しかし、パンデミックの間、肺がんの手術の遅れが見られました。COVID-19は、私たちの肺がんセンターにおける肺がん患者の診断と治療パターンに大きな影響を与えたようです。多くの腫瘍医は、来年、新たに肺がんと診断される患者数が増加することを懸念しています。この研究はまだ進行中であり、COVID-19パンデミックが私たちの肺がん患者集団に及ぼす全体的な影響をよりよく理解するために、より多くの情報が収集され、分析される予定です。
最近の動向
- 2022年10月、クエスト・ダイアグノスティクスはデコード・ヘルスとのパートナーシップの新たな章を発表しました。このパートナーシップにより、同社は新たな診断テストの作成やさまざまながんに対する新たな治療ターゲットの発見にかかる時間と費用を削減し、中東およびアフリカでのプレゼンスを高めることができました。
- 2022年8月、F.ホフマン・ラ・ロシュ社は、臨床研究者が患者のがん、遺伝性疾患、または感染症の性質をよりよく理解するのに役立つ次世代デジタルPCRシステムであるデジタルライトサイクラーシステムの発売を発表しました。このシステムは、腫瘍学および感染症における高感度で正確なDNAおよびRNA分析を行う研究室向けに設計されています。
中東およびアフリカの肺がん診断市場の範囲
中東およびアフリカの肺がん診断市場は、製品タイプ、検査タイプ、がんタイプ、エンドユーザー、流通チャネルに基づいて、5 つの主要なセグメントに分類されています。これらのセグメントの成長は、業界のわずかな成長セグメントの分析に役立ち、ユーザーに貴重な市場概要と市場洞察を提供して、コア市場アプリケーションを特定するための戦略的決定を下すのに役立ちます。
製品タイプ
- 楽器
- 消耗品とアクセサリー
製品タイプに基づいて、中東およびアフリカの肺がん診断市場は、機器、消耗品、付属品に分類されます。
テストの種類
- バイオマーカー検査
- 画像検査
- 生検
- 血液検査
- その他
検査の種類に基づいて、中東およびアフリカの肺がん診断市場は、画像検査、バイオマーカー検査、生検、血液検査などに分類されます。
がんの種類
- 非小細胞肺がん
- 小細胞肺がん
がんの種類に基づいて、中東およびアフリカの肺がん診断市場は、非小細胞肺がんと小細胞肺がんに分類されます。
エンドユーザー
- 病院
- 関連ラボ
- 独立診断研究所
- 画像診断センター
- がん研究機関
- その他
エンドユーザーに基づいて、中東およびアフリカの肺がん診断市場は、病院、関連研究所、独立した診断研究所、診断画像センター、がん研究機関などに分類されます。
流通チャネル
- 直接入札
- 小売販売
流通チャネルに基づいて、中東およびアフリカの肺がん診断市場は、直接入札と小売販売に分類されます。
中東およびアフリカの肺がん診断市場の地域分析/洞察
中東およびアフリカの肺がん診断市場が分析され、上記のように国、製品タイプ、検査タイプ、がんタイプ、エンドユーザー、流通チャネル別に市場規模の洞察と傾向が提供されます。
中東およびアフリカの肺がん診断市場に含まれる国としては、南アフリカ、サウジアラビア、UAE、エジプト、オマーン、バーレーン、カタール、クウェート、その他の中東およびアフリカ諸国などがあります。
肺がんの発生率増加に対する認識が高まっているため、南アフリカが中東およびアフリカの肺がん診断市場を支配すると予想されています。
レポートの国別セクションでは、市場の現在および将来の動向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。下流および上流のバリュー チェーン分析、技術動向、ポーターの 5 つの力の分析、ケース スタディなどのデータ ポイントは、個々の国の市場シナリオを予測するために使用される指標の一部です。また、中東およびアフリカのブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面する課題、国内関税と貿易ルートの影響を考慮しながら、国別データの予測分析を提供します。
競争環境と中東およびアフリカの肺がん診断市場シェア分析
中東およびアフリカの肺がん診断市場の競争環境は、競合他社によって詳細が提供されています。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、中東およびアフリカでのプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、中東およびアフリカの肺がん診断市場への会社の焦点にのみ関連しています。
中東およびアフリカ市場のプレーヤーとしては、F. Hoffmann-La Roche Ltd.、Thermo Fisher Scientific Inc.、Abbott、Quest Diagnostics Incorporated、Biodesix、Amoy Diagnostics Co., Ltd.、Bio-Rad Laboratories, Inc.、Biocartis、Boditech Med Inc.、Danaher、Vela Diagnostics、DiaSorin SpA、Exact Sciences UK, Ltd. (Exact Science Corporation の子会社)、20/20 Gene Systems、Guardant Health, Inc.、Inivata Ltd.、LalPathLabs.com、LungLife AI, Inc.、MedGenome、Myriad Genetics, Inc.、NeoGenomics Laboratories、NanoString、Nanoentek、Oncocyte Corporation、PerkinElmer Inc.、PlexBio、QIAGEN、Siemens Healthcare GmbH、Veracyte, Inc. などがあります。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 INDUSTRY INSIGHTS
5 EPIDERMIOLOGY
6 REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION
7.1.2 INCREASING EARLY DIAGNOSIS OF LUNGS CANCER
7.1.3 INCREASING CASES OF LUNG CANCER
7.1.4 RISE IN PRODUCT APPROVALS
7.2 RESTRAINTS
7.2.1 POOR & LATE DIAGNOSIS OF LUNG CANCER
7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY
7.3 OPPORTUNITIES
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS
7.3.3 RISING AWARENESS OF LUNG CANCER
7.4 CHALLENGES
7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS
7.4.2 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES
7.4.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
8 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.2.1 IMAGING INSTRUMENTS
8.2.1.1 CT SYSTEMS
8.2.1.2 ULTRASOUND SYSTEMS
8.2.1.3 MRI SYSTEMS
8.2.1.4 OTHERS
8.2.2 BIOPSY INSTRUMENTS
8.2.2.1 NEEDLE BIOPSY
8.2.2.2 ENDOSCOPIC BIOPSY
8.2.2.3 CORE BIOPSY
8.2.2.4 OTHERS
8.2.3 PATHOLOGY-BASED INSTRUMENTS
8.2.3.1 SLIDE STAINING SYSTEMS
8.2.3.2 TISSUE PROCESSING SYSTEMS
8.2.3.3 CELL PROCESSORS
8.2.3.4 PCR INSTRUMENTS
8.2.3.5 OTHERS PATHOLOGY-BASED INSTRUMENTS
8.3 CONSUMABLES AND ACCESSORIES
8.3.1 KITS
8.3.1.1 DNA POLYMERASE KITS
8.3.1.2 NUCLEIC ACID ISOLATION KITS
8.3.1.3 PCR KITS
8.3.1.4 OTHERS
8.3.2 REAGENTS
8.3.2.1 ASSAYS
8.3.2.2 BUFFERS
8.3.2.3 PRIMERS
8.3.2.4 OTHERS
8.3.3 PROBES
8.3.4 OTHER CONSUMABLES
9 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING TEST
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN
9.2.2 POSITRON EMISSION TOMOGRAPHY (PET) SCAN
9.2.3 CHEST X-RAY
9.2.4 BONE SCAN
9.2.5 MRI
9.2.6 OTHERS
9.3 BIOMARKERS TEST
9.3.1 EGFR MUTATION TEST
9.3.2 KRAS MUTATION TEST
9.3.3 ALK TEST
9.3.4 HER2 TEST
9.3.5 OTHERS
9.4 BIOPSY
9.4.1 NEEDLE BIOPSY
9.4.2 BRONCHOSCOPY BIOPSY
9.4.3 CORE BIOPSY
9.4.4 OTHERS
9.5 BLOOD TEST
9.5.1 COMPLETE BLOOD COUNT (CBC)
9.5.2 BLOOD CHEMISTRY TESTS
9.5.3 OTHERS
9.6 OTHERS
10 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 NON-SMALL CELL LUNG CANCER
10.3 SMALL CELL LUNG CANCER
11 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITAL
11.3 ASSOCIATED LABS
11.4 INDEPENDENT DIAGNOSTIC LABORATORIES
11.5 DIAGNOSTIC IMAGING CENTERS
11.6 CANCER RESEARCH INSTITUTES
11.7 OTHERS
12 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
13 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 SOUTH AFRICA
13.1.2 EGYPT
13.1.3 SAUDI ARABIA
13.1.4 U.A.E.
13.1.5 KUWAIT
13.1.6 OMAN
13.1.7 BAHRAIN
13.1.8 QATAR
13.1.9 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 F. HOFFMANN-LA ROCHE LTD. (2022)
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 THERMO FISHER SCIENTIFIC INC. (2022)
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 ABBOTT (2022)
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 QUEST DIAGNOSTICS INCORPORATED (2022)
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 BIODESIX (2022)
16.5.1 COMPANY PROFILE
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENTS
16.6 AMOY DIAGNOSTICS CO., LTD. (2022)
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 BIO-RAD LABORATORIES, INC. (2022)
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENTS
16.8 BIOCARTIS (2022)
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENTS
16.9 BODITECH MED INC.
16.9.1 COMPANY PROFILE
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENTS
16.1 DANAHER (2022)
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENTS
16.11 DIASORIN S.P.A. (2022)
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENTS
16.12 EXACT SCIENCES UK, LTD. (SUBSIDIARY OF EXACT SCIENCE CORPORATION) (2022)
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENTS
16.13 20/20 GENE SYSTEMS
16.13.1 COMPANY PROFILE
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 GUARDANT HEALTH INC.
16.14.1 COMPANY PROFILE
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENTS
16.15 INIVATA LTD.
16.15.1 COMPANY PROFILE
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENTS
16.16 LALPATHLABS.COM (2022)
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENTS
16.17 LUNGLIFE AI, INC. (2022)
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 MEDGENOME
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENTS
16.19 MYRIAD GENETICS, INC.
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENTS
16.2 NEOGENOMICS LABORATORIES (2022)
16.20.1 COMPANY SNAPSHOT
16.20.2 REVENUE ANALYSIS
16.20.3 PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENTS
16.21 NANOSTRING (2022)
16.21.1 COMPANY SNAPSHOT
16.21.2 REVENUE ANALYSIS
16.21.3 PRODUCT PORTFOLIO
16.21.4 RECENT DEVELOPMENTS
16.22 NANOENTEK
16.22.1 COMPANY PROFILE
16.22.2 PRODUCT PORTFOLIO
16.22.3 RECENT DEVELOPMENTS
16.23 ONCOCYTE CORPORATION
16.23.1 COMPANY PROFILE
16.23.2 SERVICE PORTFOLIO
16.23.3 RECENT DEVELOPMENTS
16.24 PERKINELMER INC
16.24.1 COMPANY PROFILE
16.24.2 REVENUE ANALYSIS
16.24.3 PRODUCT PORTFOLIO
16.24.4 RECENT DEVELOPMENTS
16.25 PLEXBIO
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENTS
16.26 QIAGEN
16.26.1 COMPANY SNAPSHOT
16.26.2 REVENUE ANALYSIS
16.26.3 PRODUCT PORTFOLIO
16.26.4 RECENT DEVELOPMENTS
16.27 SIEMENS HEALTHCARE GMBH
16.27.1 COMPANY SNAPSHOT
16.27.2 REVENUE ANALYSIS
16.27.3 PRODUCT PORTFOLIO
16.27.4 RECENT DEVELOPMENTS
16.28 VERACYTE, INC. (2022)
16.28.1 COMPANY SNAPSHOT
16.28.2 REVENUE ANALYSIS
16.28.3 PRODUCT PORTFOLIO
16.28.4 RECENT DEVELOPMENTS
16.29 VELA DIAGNOSTICS
16.29.1 COMPANY PROFILE
16.29.2 PRODUCT PORTFOLIO
16.29.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
表のリスト
TABLE 1 DIFFERENT TYPES OF CANCER SCREENING TESTS FOR DIFFERENT TYPES OF CANCERS
TABLE 2 LUNG CANCER RATES
TABLE 3 APPROVED DIAGNOSTICS OF LUNGS CANCER
TABLE 4 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA CONSUMABLES & ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA OTHERS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA SMALL CELL LUNG CANCER IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA HOSPITAL IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA ASSOCIATED LABS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA INDEPENDENT DIAGNOSTIC LABORATORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA DIAGNOSTIC IMAGING CENTERS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA CANCER RESEARCH INSTITUTES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA OTHERS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA DIRECT TENDER IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA RETAIL SALES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 53 SOUTH AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 54 SOUTH AFRICA INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 SOUTH AFRICA PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 SOUTH AFRICA IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 57 SOUTH AFRICA BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 58 SOUTH AFRICA CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 59 SOUTH AFRICA KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 60 SOUTH AFRICA REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 61 SOUTH AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 62 SOUTH AFRICA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 63 SOUTH AFRICA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 64 SOUTH AFRICA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 65 SOUTH AFRICA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 66 SOUTH AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 67 SOUTH AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 68 SOUTH AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 69 EGYPT LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 70 EGYPT INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 71 EGYPT PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 EGYPT IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 EGYPT BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 74 EGYPT CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 75 EGYPT KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 76 EGYPT REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 77 EGYPT LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 78 EGYPT BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 79 EGYPT IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 80 EGYPT BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 81 EGYPT BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 82 EGYPT LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 83 EGYPT LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 84 EGYPT LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 85 SAUDI ARABIA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 86 SAUDI ARABIA INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 87 SAUDI ARABIA PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 88 SAUDI ARABIA IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 89 SAUDI ARABIA BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 90 SAUDI ARABIA CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 91 SAUDI ARABIA KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 92 SAUDI ARABIA REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 93 SAUDI ARABIA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 94 SAUDI ARABIA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 95 SAUDI ARABIA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 96 SAUDI ARABIA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 97 SAUDI ARABIA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 98 SAUDI ARABIA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 99 SAUDI ARABIA LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 100 SAUDI ARABIA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 101 U.A.E LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 102 U.A.E INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 103 U.A.E PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 104 U.A.E IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 105 U.A.E BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 106 U.A.E CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 107 U.A.E KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 108 U.A.E REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 109 U.A.E LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 110 U.A.E BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 111 U.A.E IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 112 SAUDI ARABIA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 113 U.A.E BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 114 U.A.E LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 115 U.A.E LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 116 U.A.E LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 117 KUWAIT LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 118 KUWAIT INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 119 KUWAIT PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 120 KUWAIT IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 121 KUWAIT BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 122 KUWAIT CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 123 KUWAIT KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 124 KUWAIT REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 125 KUWAIT LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 126 KUWAIT BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 127 KUWAIT IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 128 KUWAIT BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 129 KUWAIT BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 130 KUWAIT LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 131 KUWAIT LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 132 KUWAIT LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 133 OMAN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 134 OMAN INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 135 OMAN PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 136 OMAN IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 137 OMAN BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 138 OMAN CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 139 OMAN KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 140 OMAN REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 141 OMAN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 142 OMAN BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 143 OMAN IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 144 OMAN BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 145 OMAN BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 146 OMAN LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 147 OMAN LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 148 OMAN LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 149 BAHRAIN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 150 BAHRAIN INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 151 BAHRAIN PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 152 BAHRAIN. IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 153 BAHRAIN BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 154 BAHRAIN CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 155 BAHRAIN KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 156 BAHRAIN REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 157 BAHRAIN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 158 BAHRAIN BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 159 BAHRAIN IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 160 BAHRAIN BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 161 BAHRAIN BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 162 BAHRAIN LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 163 BAHRAIN LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 164 BAHRAIN LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 165 QATAR LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 166 QATAR INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 167 QATAR PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 168 QATAR IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 169 QATAR BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 170 QATAR CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 171 QATAR KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 172 QATAR REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 173 QATAR LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 174 QATAR BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 175 QATAR IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 176 QATAR BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 177 QATAR BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 178 QATAR LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 179 QATAR LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 180 QATAR LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 181 REST OF MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
図表一覧
FIGURE 1 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA LUNGS CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT LUNG CANCER IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD
FIGURE 12 INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET
FIGURE 14 THE MIDDLE EAST & AFRICA MORTALITY RATE DUE TO CANCER
FIGURE 15 THE DATA GIVEN BELOW SHOWS THE INCREASING MIDDLE EAST & AFRICA CANCER RATE IN 2020
FIGURE 16 BARRIERS TO EARLY CANCER DIAGNOSIS AND TREATMENT
FIGURE 17 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 18 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 19 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 20 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 21 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 22 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 23 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 24 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 25 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 26 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 27 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 28 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 29 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 30 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 31 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 32 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 33 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 34 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 35 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 36 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 37 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 38 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 39 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 40 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 41 MIDDLE EAST AND AFRICA LUNG CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 42 MIDDLE EAST & AFRICA LUNG CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
